Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ahmad Bushehri"'
Autor:
Shatha Abutaha, Layth Mula-Hussain, Mostafa ElHaddad, Sara Sami, Khawla Ammar, Zineb Dahbi, Caroline Jabbour, Ugur Selek, Ramiz Abu-Hijlih, Akram Al-Ibraheem, Fawzi Abuhijla, Ahmed Abbasi, Ahmad Bushehri, Ibrahim Alotain, Mohammed Aldehaim, Majed Alghamdi, Ibrahim Abu-Gheida, Nadeem Pervez, Bassem Youssef, Saad Alrashidi, Wael El-sheshtawy, Ali Hosni, Issa Mohamad
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEThis study aims to assess the status of radiation oncology peer review procedures across the Middle East, North Africa, and Türkiye (MENAT) region.METHODSA cross-sectional electronic survey was conducted among radiotherapy centers in the MENA
Externí odkaz:
https://doaj.org/article/3864b564d69840dcaeb3a466b9d00e88
Autor:
Eric Y. Zhao, Ahmad Bushehri, Biu Chan, Olive Wong, Jenny Lee, Tirth Patel, Sejin Kim, Ian King, Shao Hui Huang, John Cho, Ezra Hahn, Ali Hosni Abdalaty, John Kim, Jolie Ringash, Brian O’sullivan, John N. Waldron, Jean-Pierre Bissonnette, Meredith E. Giuliani, Benjamin Haibe-Kains, Tony Tadic, Andrea McNiven, Andrew Hope, Scott V. Bratman
Publikováno v:
Radiotherapy and Oncology. 174:S54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc77c40d9ecc7155e9dfa01589240da5
https://doi.org/10.1016/s0167-8140(22)04404-8
https://doi.org/10.1016/s0167-8140(22)04404-8
Autor:
Kullervo Hynynen, Charles Mougenot, Carlo DeAngelis, Liying Zhang, Ahmad Bushehri, Arjun Sahgal, Jennifer Coccagna, William Chu, Yuexi Huang, Edward Chow, Gregory J. Czarnota, Michael Chan, Kristopher Dennis
Publikováno v:
Annals of Palliative Medicine. 6:36-54
Background: Pain is experienced by 50–75% of patients with bone metastases, representing a major source of morbidity amongst cancer patients. Magnetic resonance-guided high intensity focused ultrasound (MRgHIFU) is a new, non-invasive, outpatient t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2c53cb256bd8f4b529cb89bfcaa25b
https://doi.org/10.21037/apm.2016.12.06
https://doi.org/10.21037/apm.2016.12.06
Autor:
Erin McKenzie, William Pidduck, Carlo DeAngelis, Katarzyna J. Jerzak, Yasmeen Razvi, Stephanie Chan, Ahmad Bushehri, Pearl Zaki, Edward Chow, Thomas McFarlane
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 27(1)
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent changes in the optimal management of CINV, we undertook this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52f49de99830d77a2839edc19876fede
https://pubmed.ncbi.nlm.nih.gov/30284039
https://pubmed.ncbi.nlm.nih.gov/30284039
Autor:
Jennifer Coccagna, Kullervo Hynynen, Charles Mougenot, Carlo DeAngelis, Ahmad Bushehri, Kristopher Dennis, Gregory J. Czarnota, Edward Kai-Hua Chow, Arjun Sahgal, Liying Zhang, Michael Chan, Yuexi Huang, W. Chu
Publikováno v:
Radiotherapy and Oncology. 120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90769a6a990943d377a9bb5e0075282b
Autor:
Rachel McDonald, Ahmad Bushehri, Carlo DeAngelis, Michelle Zhou, Kristopher Dennis, Azar Azad, Edward Chow, Mark Pasetka, Sherlyn Vuong, Liying Zhang, Amanda Hird
Publikováno v:
Annals of palliative medicine. 5(2)
Background: External beam radiotherapy (EBRT) is a mainstay for treatment of painful bone metastases. Transient worsening of pain (“pain flare”) occurs in 40% of patients. We investigated the pathophysiology of pain flare through assessment of ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be6ba44603cc867ccf087c6c19ec36ef
https://pubmed.ncbi.nlm.nih.gov/27121738
https://pubmed.ncbi.nlm.nih.gov/27121738
Publikováno v:
Retinal Cases & Brief Reports
This is the first case that describes bilateral, multifocal central serous retinopathy appearing 2 days after starting pimasertib for ovarian cancer and rapidly resolving 3 days after stopping pimasertib. Pimasertib is an orally bioavailable MEK 1 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fce4aafdb92de1c9cc2617f2a57d70c
https://pubmed.ncbi.nlm.nih.gov/26444523
https://pubmed.ncbi.nlm.nih.gov/26444523